Cover Image

Study Duration Prediction for Clinical Trials with Time-to-Event Endpoints Using Mixture Distributions Accounting for Heterogeneous Population

Fuente: arXiv

Saved in:

Bibliographic Details
Main Authors:	Zhang, Hong, Pu, Jie, Deng, Shibing, Roychoudhury, Satrajit, Chu, Haitao, Robinson, Douglas
Format:	Preprint
Published:	2023
Subjects:	Methodology Applications
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Dynamic Prediction of the Target Survival Time in Metastatic Solid Tumor Cancer Clinical Trials
by: Wang, Sidi, et al.
Published: (2026)

A robust score test in g-computation for covariate adjustment in randomized clinical trials leveraging different variance estimators via influence functions
by: Zhang, Xin, et al.
Published: (2025)

Fragility Index for Time-to-Event Endpoints in Single-Arm Clinical Trials
by: Maity, Arnab Kumar, et al.
Published: (2024)

On regional treatment effect assessment using robust MAP priors
by: Zhang, Xin, et al.
Published: (2026)

Toward Valid Generative Clinical Trial Data with Survival Endpoints
by: Chassat, Perrine, et al.
Published: (2025)

Bias in Meta-Analytic Modeling of Surrogate Endpoints in Cancer Screening Trials
by: Long, James P., et al.
Published: (2025)

Evaluating treatment effects on longitudinal outcomes with attrition due to death: Methods for a two-dimentional estimand with a case study in Quality of Life
by: Reynders, Dries, et al.
Published: (2025)

Mixture of Finite Mixtures Model for Basket Trial
by: Geng, Junxian, et al.
Published: (2020)

Heterogeneous Clinical Trial Outcomes via Multi-Output Gaussian Processes
by: Thomas, Owen, et al.
Published: (2024)

A Workflow for Evaluating Regional Treatment Effect Heterogeneity in Multi-Regional Clinical Trials
by: Zhang, Cong, et al.
Published: (2026)

Power and Sample Size Calculations for Bayes Factors in two-arm clinical Phase II Trials with binary Endpoints
by: Kelter, Riko
Published: (2026)

Optimal sequential two-stage Bayes Factor Design for two-arm clinical Phase II Trials with binary Endpoints
by: Kelter, Riko
Published: (2026)

A Bayesian Discrete Framework for Enhancing Decision-Making Processes in Clinical Trial Designs and Evaluations
by: Pramanik, Paramahansa, et al.
Published: (2026)

Bias reduction in g-computation for covariate adjustment in randomized clinical trials
by: Zhang, Xin, et al.
Published: (2025)

Semiparametric Piecewise Accelerated Failure Time Model for the Analysis of Immune-Oncology Clinical Trials
by: Sunami, Hisato, et al.
Published: (2024)

Uncovering Treatment Effect Heterogeneity in Pragmatic Gerontology Trials
by: Li, Changjun, et al.
Published: (2025)

Statistical Inference for Heterogeneous Treatment Effect with Right-censored Data from Synthesizing Randomized Clinical Trials and Real-world Data
by: Mao, Guangcai, et al.
Published: (2025)

Evaluation of Surrogate Endpoints Based on Meta-Analysis with Surrogate Indices
by: Stijven, Florian, et al.
Published: (2025)

Prediction Intervals for Interim Events in Randomized Clinical Trials with Time-to-Event Endpoints
by: Ratti, Edoardo, et al.
Published: (2026)

Precision Mental Health: Predicting Heterogeneous Treatment Effects for Depression through Data Integration
by: Brantner, Carly L., et al.
Published: (2025)

On the Calibration of Bayesian Success Criteria and Operating Characteristics for Clinical Trials
by: Yang, Peng, et al.
Published: (2026)

[Invited Discussion] Randomization Tests to Address Disruptions in Clinical Trials: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions
by: Phillips, Rachael V., et al.
Published: (2024)

Backward Joint Model for the Joint Dynamic Prediction of Time-to-Event and Longitudinal Data: Basic Formulation and New Developments
by: Li, Wenhao, et al.
Published: (2023)

E-values for Adaptive Clinical Trials: Anytime-Valid Monitoring in Practice
by: Sokolova, Alexandra, et al.
Published: (2026)

Identifying Treatment Effect Heterogeneity with Bayesian Hierarchical Adjustable Random Partition in Adaptive Enrichment Trials
by: Zhao, Xianglin, et al.
Published: (2025)

Improving the Estimation of Site-Specific Effects and their Distribution in Multisite Trials
by: Lee, JoonHo, et al.
Published: (2023)

Accounting for Heavy Censoring in Evaluating the Risk Stratification Abilities of Existing Models for Time to Diagnosis of Huntington Disease
by: Grosser, Kyle F., et al.
Published: (2025)

Correcting for Missing Data When Evaluating Surrogate Markers in a Clinical Trial
by: Lotspeich, Sarah C., et al.
Published: (2026)

Tutorial for Surrogate Endpoint Validation Using Joint modeling and Mediation Analysis
by: Coent, Quentin Le, et al.
Published: (2025)

Multi-Dimensional Composite Endpoint Analysis via the Choquet Integral: Block Recurrent Encoding and Comparative Advantage Mapping
by: Tanboga, Ibrahim Halil
Published: (2026)

A Finite Mixture Hidden Markov Model for Intermittently Observed Disease Process with Heterogeneity and Partially Known Disease Type
by: Shi, Yidan, et al.
Published: (2024)

Distribution-Free Prediction Bands for Multivariate Functional Time Series: an Application to the Italian Gas Market
by: Diquigiovanni, Jacopo, et al.
Published: (2021)

Shifting the Paradigm: Estimating Heterogeneous Treatment Effects in the Development of Walkable Cities Design
by: Zhu, Jie, et al.
Published: (2024)

A General Mixture Loss Function to Optimize a Personalized Predictive Model
by: Krikella, Tatiana, et al.
Published: (2026)

A Bayesian Treatment Selection Design for Phase II Randomised Cancer Clinical Trials
by: Komaki, Moka, et al.
Published: (2025)

Sample Size Calculations for the Development of Risk Prediction Models that Account for Performance Variability
by: Pavlou, Menelaos, et al.
Published: (2025)

Population Size Estimation with Many Lists and Heterogeneity: A Conditional Log-Linear Model Among the Unobserved
by: Rubio, Mateo Dulce, et al.
Published: (2024)

Age-Specific Logistic Regression with Complex Event Time Data
by: Haoxuan, et al.
Published: (2026)

Adaptive Weighting for Time-to-Event Continual Reassessment Method: Improving Safety in Phase I Dose-Finding Through Data-Driven Delay Distribution Estimation
by: Amevor, Robert, et al.
Published: (2026)

A Utility Score Framework for Dose Optimization Studies with Binary Efficacy-Safety Endpoints: Sample Size Determination and Bias Characterization
by: Gu, Xuemin, et al.
Published: (2026)